IMU (ASX) Ann: Termination of Supply Agreement

Originally posted by Brightshiny1: ↑

https://www.msd-australia.com.au/news/cancer-therapies-receive-recommendations-from-the-pharmaceutical-benefits-advisory-committee/27/4/2021

KEYTRUDA SELECTED SAFETY INFORMATION2 Precautions: Immune-mediated adverse reactions (ImARs), incl. severe and fatal cases, have occurred in patients receiving KEYTRUDA. These have included, but not limited to: pneumonitis, colitis, hepatitis, hepatoxicity (in combination with axitinib), nephritis, endocrinopathies (adrenal insufficiency, hypophysitis, type 1 diabetes mellitus, hyperthyroidism, hypothyroidism, thyroiditis), severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis and bullous pemphigoid), uveitis, myositis, Guillain-Barre syndrome, pancreatitis, encephalitis, sarcoidosis, myasthenic syndrome/myasthenia gravis (incl. exacerbation), myelitis, vasculitis, myocarditis, pericarditis and pericardial effusion, peripheral neuropathy, sclerosing cholangitis, solid organ transplant rejection, severe infusion reactions (hypersensitivity, anaphylaxis) and complications of allogeneic HSCT. ImARs have occurred after discontinuation of treatment with KEYTRUDA. ImARs can affect more than one body system simultaneously. Thyroid and liver function tests should be performed at baseline, periodically during treatment and as indicated based on clinical evaluation. Withhold or discontinue KEYTRUDA to manage adverse reactions as described in the Product Information. Adverse events: In patients with endometrial carcinoma treated with KEYTRUDA/LENVIMA, the following adverse events occurred at a rate >20% and at a rate higher than doxorubicin or paclitaxel were: hypothyroidism (67% vs 0.9%), hypertension (67% vs 6%), haemorrhagic events (25% vs 15%), fatigue (58% vs 54%), diarrhoea (55% vs 20%), nausea (49% vs 47%), vomiting (37% vs 21%), stomatitis (35% vs 26%), abdominal pain (34% vs 21%), constipation (27% vs 25%), musculoskeletal disorders (53% vs 27%), decreased appetite (44% vs 21%), weight loss (34% vs 6%), proteinuria (29% vs 3.4%), urinary tract infection (31% vs 13%) , headache (26% vs 9%), dysphonia (22% vs 0.6%), palmar-plantar erythrodysesthesia (23% vs 0.9%) and rash (20% vs 4.9%). Fatal adverse events have occurred. In patients with head and neck cancer, KEYTRUDA was discontinued for adverse reactions in 12% of patients in the KEYTRUDA single agent arm. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA were sepsis (1.7%) and pneumonia (1.3%). Adverse reactions leading to the interruption of KEYTRUDA occurred in 31% of patients; the most common adverse reactions leading to interruption of KEYTRUDA (≥2%) were pneumonia (2.3%), pneumonitis (2.3%), and hyponatremia (2%). KEYTRUDA was discontinued for adverse reactions in 16% of patients in the combination arm. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA were pneumonia (2.5%), pneumonitis (1.8%), and septic shock (1.4%). Adverse reactions leading to the interruption of KEYTRUDA occurred in 45% of patients; the most common adverse reactions leading to interruption of KEYTRUDA (≥2%) were neutropenia (14%), thrombocytopenia (10%), anaemia (6%), pneumonia (4.7%), and febrile neutropenia (2.9%). Contraindications: None.Refer to the Consumer Medical Information leaflet, available online or your doctor or pharmacist for further information about KEYTRUDA.I'm guessing that this has something to do with it, an article from MSD website last week, Imugene probably has cold feet.

Expand

But if they had cold feet, why would they continue with the trial?I m reading it that they continue with the trial, but now will supply Merck product for it.

No.	Vol.	Price($)
1	348447	5.4¢

No.

Vol.

Price($)

348447

5.4¢

Price($)	Vol.	No.
5.5¢	1214875	6

Price($)

Vol.

No.

5.5¢

1214875

No.	Vol.	Price($)
1	348447	0.054
9	425998	0.053
13	2137592	0.052
21	4150130	0.051
39	3576889	0.050

No.

Vol.

Price($)

348447

0.054

425998

0.053

2137592

0.052

4150130

0.051

3576889

0.050

Price($)	Vol.	No.
0.055	700000	4
0.056	556147	3
0.057	1055166	8
0.058	410000	6
0.059	292981	9

Price($)

Vol.

No.

0.055

700000

0.056

556147

0.057

1055166

0.058

410000

0.059

292981

(20min delay)
Last 5.5¢		Change 0.003(5.77%)		Mkt cap ! $404.2M

Open	High	Low	Value	Volume
5.2¢	5.7¢	5.2¢	$802.5K	14.79M

Ann: Termination of Supply Agreement, page-97

Emerald & Azure score Digger & Dealer awards

Revolutionary inverter technology leads the clean energy charge

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Bitcoin: Current State of Play & Where to Next | Swyftx

True North increases silver metal at QLD's Vero deposit by 20%

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Termination of Supply Agreement, page-97

Top Stories

Emerald & Azure score Digger & Dealer awards

Revolutionary inverter technology leads the clean energy charge

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Bitcoin: Current State of Play & Where to Next | Swyftx

True North increases silver metal at QLD's Vero deposit by 20%

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News